Soliris (eculizumab) helped ease disease symptoms for a woman with multiple myeloma who developed atypical hemolytic uremic syndrome…
Articles by Margarida Maia, PhD
Soliris (eculizumab) is safe and effective for treating children with various types of hemolytic uremic syndrome (HUS), including…
COVID-19 was the likely trigger of atypical hemolytic uremic syndrome (aHUS) in a boy found to carry a mutation…
The pregnancy-related complication HELLP syndrome — fully known as hemolysis, elevated liver enzymes, and low platelets syndrome, which causes high…
Soliris (eculizumab) largely reduces the risk of long-term kidney problems in women who develop atypical hemolytic uremic syndrome…
The use of a C5 inhibitor — with or without plasma exchange — was found to work better than supportive…
Genetic testing may allow for the timely use of anti-complement therapy for atypical hemolytic uremic syndrome (aHUS), even if…
The use of Soliris (eculizumab) is changing the natural course of atypical hemolytic uremic syndrome (aHUS) in Latin…
Adults with atypical hemolytic uremic syndrome (aHUS) who switched from Soliris (eculizumab) to long-acting Ultomiris (ravulizumab) in…
The U.S. Food and Drug Administration (FDA) has approved Bkemv (eculizumab-aeeb), the first interchangeable biosimilar to Soliris (eculizumab), to treat…